Antibody-drug conjugates (ADCs) are targeted therapies that link cytotoxic drugs to antibodies, enhancing efficacy while minimizing side effects. Alphamab has developed a proprietary glycan-specific conjugation platform for precise and controllable conjugation, thereby improving the therapeutic window. Building on bispecific antibody technology, Alphamab has developed bispecific ADCs (BADC) and dual-drug conjugates (BADDC), improving tumor targeting and addressing heterogeneity and resistance issues, offering new strategies for cancer treatment.

With multiple proprietary platforms, Alphamab Oncology has established a globally competitive and differentiated pipeline that includes single domain antibody, bispecific antibodies, and ADCs. Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor, was approved in China in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are in Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Two products were selected into the China’s "New Drug Development" project, and three products were granted 4 orphan drug qualifications by FDA.